Target species: Cats greater than or equal to 4 kg bodyweight.
Indications for use, specifying the target species
The product is intended for the 6-month long-term prevention and control of flea infestations and the treatment of FAD (flea allergic dermatitis) in cats. The product is effective against the pre-audit stages of the dominant flea species, Ctenocephalides felis and C. canis. It can be administered to all cats, including weaned kittens as well as pregnant and lactating queens.
Special warnings for each target species
Not to be used in dogs.
In the cat, to achieve a six month flea control, a small subcutaneous depot is required. Injection site reaction may occur in some cats, in particular a small painless swelling at the injection site which disappears, in general, after a few weeks
Special precautions for use
i.Special precautions for use in animals
For subcutaneous administration only.
The injection should be carried out under aseptic conditions.
ii.Special precautions to be taken by the person administering the medicinal product to the animals
Care should be taken to avoid accidental self injection. In the case of accidental self injection seek medical advice.
Avoid contact with skin and eyes. In the event of accidental eye or skin contact, wash/irrigate the area with clean running water.
Seek medical attention if irritation persists.
Wash hands after use.
Adverse reactions (frequency and seriousness)
The product is well tolerated by all cats but may cause a transient mild and painless reaction at the injection site. In rare cases, lethargy may occur for a few hours after injection, however, it quickly disappears
Use during pregnancy, lactation or lay
No harmful effects are to be expected when this product is given during pregnancy and lactation.
Interaction with other medicinal products and other forms of interaction
No evidence of interactions with other medicaments has been observed
Amounts to be administered and administration route
The minimum recommended dose is 10 mg Lufenuron per kg bodyweight when administered parenterally.
Weight of cats
Less than 4 kg
Equal to or greater than 4 kg
1 PROGRAM 40mg Suspension for Injection Syringe
80 mg Suspension for Injection Syringe
For the product to be fully effective, the whole content of the syringe must be injected subcutaneously, e.g. dorsally anterior to the shoulder blades. It is recommended that cats be re-treated at 6-month intervals to ensure continuous effective control of flea development.
The syringe must be shaken vigorously to reconstitute the suspension and then injected immediately.
If cats have a high level of flea infestation at the start of treatment, it may be necessary to apply a flea adulticide during the first one or two months. In cases of severe hypersensitivity further use of an adulticide may be needed. It is essential that all cats (except for unweaned kittens) living in a household are treated to stop flea infestation. Dogs in the same household should be treated as recommended by the prescribing veterinary surgeon.
Overdose (symptoms, emergency procedures, antidotes) if necessary
No significant untoward effects due to overdosing have been observed in the target animal safety studies.